WU Song
Principal Investigator
Professor Wu joined the Institute of Materia Medica in 1989. He was then promoted to associate professor in 1994 and to full professor in 1997. Currently, he is director of the Department of New Drug Research and Development, member of the Chinese Pharmacopoeia Commission. He is the director of CMC for several new drug R&D projects. The hypolipidemic compound will be registered for clinical trial very soon. The drug candidate for NASH is in pre-clinical study. He has completed the development of more than 20 generic drugs, published more than 140 papers in professional journals, and applied for nearly 40 patents. He is a principal investigator of more than 30 grants and has won multiple national, provincial and ministerial awards including the Science and Technology Award for Chinese Youths.
1. Metallaphotoredox -catalyzed C–H activation: regio-selective annulation of allenes with benzamide. Org Chem Front, 2021, 8(5):928-935.
2. Anti-MRSA Drug Discovery by Ligand-based Virtual Screening and Biological Evaluation. Bioorganic Chemistry, 2021, 114:105042.
3. N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification. European Journal of Medicinal Chemistry, 2020,188:112022.
4. Pose Filter-based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists. Journal of Chemical Information and Modeling, 2020, 60(3):1202-1214.
5. Discovery and structure-activity relationship study of phthalimidephenylpyridine conjugate as inhibitor of Wnt pathway. Bioorganic & Medicinal Chemistry Letters, 2019，29:870–872.
6. Discovery of potent PTP1B inhibitors via structure-based drug design, synthesis and in vitro bioassay of Norathyriol derivatives. Bioorganic Chemistry, 2019, 86:224-234.
7. Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2019, 168:207-220.
8. Design, synthesis, and biological evaluation of novel iso-flavones derivatives as H3R antagonists. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33((1):1545-1553.
9. The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, (1):525-535.
10. Design, synthesis, biological evaluation, and molecular docking of novel flavones as H3R inhibitors. Chemical Biology & Drug Design, 2017, 10, 90(4): 580-589.
11. Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine. Biomaterials, 2017，141:13-28.
12. Design and synthesis of conformationally constrained salinomycin derivatives. European Journal of Medicinal Chemistry，2017, 138:353-356.
13. Discovery of Novel Isoflavone Derivatives as Ache/Buche Dual-Targeted Inhibitors: Synthesis, Biological Evaluation and Molecular Modeling. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32 (1): 968-977.
14. The Development of Target-Specific Pose Filter Ensembles To Boost Ligand Enrichment for Structure-Based Virtual Screening. Journal of Chemical Information and Modeling, 2017, 57 (6):1414–1425.
15. Synthesis and biological activity of salinomycin-hydroxamic acid conjugates. Bioorganic & Medicinal Chemistry Letters, 2017, 27:1624–1626.
16. Structure–activity & structure–toxicity relationship study of salinomycin diastereoisomers and their benzoylated derivatives. Organic & Biomolecular Chemistry, 2016, 14:2840-2845.
17. A novel and efficient strategy involving a CuI catalyzed cascade reaction to synthesize acenaphtho[1,2-b]quinolone derivatives. Chinese Chemical Letters, 2016, 27(3):349-352.
